Teva Pharmaceuticals USA, a specialist in generic and specialty medicines, recently completed the purchase of three buildings in West Chester.
The purchase represents a 12-year investment in infrastructure and capital improvements.
The buildings, which Teva had been leasing, are located in the same corporate park where the company owns three other buildings. Together the facilities form a 314,000-square-foot North American research and development (R&D) campus.
The campus will be dedicated to increasing the company’s portfolio and feeding its pipeline. The focus will be primarily on biologics.
“With our late-stage biologics R&D development teams co-located on a single campus, the company has created a one-stop-shop for biologics development and clinical manufacturing,” said Mehran Yazdanian, senior director of Specialty R&D Scientific Strategy and Operations, global R&D and site head. “From cell bank to syringe, our West Chester R&D campus is home to many of the North American-based R&D teams and processes that will bring more biologics treatment options to patients, and support Teva’s global mission to improve lives.”
Currently, the campus houses laboratories where advanced preclinical and clinical testing is conducted.
Teva employs approximately 7,000 people throughout the United States. By the end of the year, roughly 650 employees will be based in West Chester.